US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Latest News about Patient Enrollment

Recent news which mentions Patient Enrollment

Axsome Therapeutics Commences Late-Stage Migraine Study
Tickers AXSM
Tags General Benzinga Biotech
From Benzinga
Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study
Tickers STOK
Tags Biotech Benzinga General
From Benzinga
Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off
Tickers ANVS
Tags Patient Enrollment ANVS Movers & Shakers
From Benzinga
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
Tickers CUE
Tags Movers & Shakers Patient Enrollment CUE
From Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
Tickers BBIO
Tags General BBIO Benzinga
From Benzinga
Palisade Bio Shares Drop Following Commencement Of Late-Stage Return Of Bowel Study
Tickers PALI
Tags Market News Health Care PALI
From Benzinga
Anixa Initiates Patient Dosing in Initial-Stage Ovarian Cancer Study
Tickers ANIX
Tags Biotech Benzinga General
From Benzinga
Virios Therapeutics Commences Mid-Stage Long-COVID Study
Tickers VIRI
Tags General Benzinga Biotech
From Benzinga
Avalo Therapeutics' Shares Climb Following Patient Dosing in Immunodeficiency Disorder Study
Tickers AVTX
Tags General Penny Stocks Biotech
From Benzinga
Kymera Therapeutics Commences Initial-Stage Oncology Trials
Tickers KYMR
Tags Patient Enrollment Small Cap Health Care
From Benzinga
Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate
Tickers APLS
Tags Biotech APLS Benzinga
From Benzinga
Moderna Commences Late-stage Study of Flu Vaccine Candidate
Tickers MRNA
Tags Biotech MRNA Benzinga
From Benzinga